ALSO NOTED: Amgen drug fails breast cancer trial; Patients want class status in Fosamax suit;

> Amgen's anemia drug Aranesp failed to shrink breast tumors in an early-stage trial of the drug against breast cancer. Report

> Lawyers for patients who say their jaws were damaged by Merck's osteoporosis drug Fosamax argued for class-action status, saying the company should pay for dentists to monitor the patients for complications. Report

> The FDA gave the nod to Alcon's new Triesence injectable drug for use in eye surgery. Report

> The Chinese company that suspended its contaminated methotrexate product in September says it will compensate victims who experienced side effects. Report

> Following an investment in Regeneron, Sanofi-Aventis' Marc Cluzel (photo) reiterated the company's plans to aggressively pursue biotech buyouts. "If there is a good deal to be done, we will do it. We are very pragmatic," Cluzel told investors. Report

> The Massachusetts Biotechnology Council has two big projects in the works: it's upping its lobbying spending and at the same time kicking off an ad campaign to boost its profile in the state. Report

And Finally... Early warning of what's next in cosmeceuticals: A skin patch that blocked the effects of a single gene reversed skin aging in mice. Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.